Abstract
Introduction: IPF is a progressive, irreversible and fatal disease. Early treatment when lung function is relatively preserved may have beneficial outcomes. Here we investigated the efficacy of pirfenidone (PFD) in patients stratified by mild vs more pronounced restrictive disease as well as by GAP stage.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
